Meeting
2018 ASCO Annual Meeting
Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.
Authors
Andrew X. Zhu
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Andrew X. Zhu , Richard S. Finn , Julien Edeline , Stéphane Cattan , Sadahisa Ogasawara , Daniel H. Palmer , Chris Verslype , Vittorina Zagonel , Laetitia Fartoux , Arndt Vogel , Debashis Sarker , Gontran Verset , Stephen Lam Chan , Jennifer J. Knox , Bruno Daniele , Scot Ebbinghaus , Junshui Ma , Abby B. Siegel , Ann-Lii Cheng , Masatoshi Kudo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02702414
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4020)
DOI
10.1200/JCO.2018.36.15_suppl.4020
Abstract #
4020
Poster Bd #
209
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
First Author: Andrew X. Zhu
Poster
2019 Gastrointestinal Cancers Symposium
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
First Author: Masatoshi Kudo
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
First Author: Todd S. Crocenzi
Poster
2017 ASCO Annual Meeting
LCCC 1525: Combination immunotherapy with cyclophosphamide plus pembrolizumab in patients with advanced triple negative breast cancer (TNBC).
First Author: Benjamin Garrett Vincent